Cancer Research Annual Meeting 2010 Jordan
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhang, X.
Right arrow Articles by Lin, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, X.
Right arrow Articles by Lin, D.
[Cancer Research 65, 722-726, February 1, 2005]
© 2005 American Association for Cancer Research

Priority Reports

Polymorphisms in DNA Base Excision Repair Genes ADPRT and XRCC1 and Risk of Lung Cancer

Xuemei Zhang1,5, Xiaoping Miao1, Gang Liang1, Bingtao Hao3,4, Yonggang Wang2, Wen Tan1, Yi Li3, Yongli Guo1, Fuchu He3,4, Qingyi Wei6 and Dongxin Lin1

Departments of 1 Etiology and Carcinogenesis and 2 Thoracic Surgery, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; 3 Department of Biology Sciences and Biotechnology, Tsinghua University; 4 Laboratory of Systems Biology, Beijing Institute of Radiation Medicine, Beijing, China; 5 Department of Biology Sciences, North China Coal Medical College, Tangshan, Hebei, China; and 6 Department of Epidemiology, University of Texas M.D. Anderson Cancer Center, Houston, Texas

Requests for reprints: Dongxin Lin, Department of Etiology and Carcinogenesis, Cancer Institute, Chinese Academy of Medical Sciences, Beijing 100021, China. Phone: 86-10-877-88491; Fax: 86-10-677-22460; E-mail: dlin{at}public.bta.net.cn.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Adenosine diphosphate ribosyl transferase (ADPRT) and X-ray repair cross-complementing 1 (XRCC1) are two major DNA base excision repair (BER) proteins and act interactively in stimulating and executing BER processes. Polymorphisms of ADPRT Val762Ala and XRCC1 Arg399Gln have been associated with altered protein function and BER activity. This case-control study examined the contribution of these two polymorphisms, alone and in combination, or in interaction with smoking, to the risk of developing lung cancer. We estimated the risk of lung cancer associated with these polymorphisms in 1,000 cases and 1,000 cancer-free controls using logistic regression models. Subjects having the ADPRT Ala/Ala genotype had an odds ratio (OR) of 1.68 [95% confidence interval (95% CI), 1.27-2.23] compared with those having the Val/Val genotype. A greater than multiplicative joint effect between the ADPRT polymorphism and smoking was observed. The ORs (95% CI) of the Ala/Ala genotype for nonsmokers and smokers who smoked ≤16, 16 to 28, or >28 pack-years were 1.13 (0.79-1.62), 1.35 (0.68-2.70), 2.46 (1.35-4.51) or 17.09 (8.15-35.83), respectively (P trend test < 0.001). Gene-gene interaction of ADPRT and XRCC1 polymorphisms increased risk of lung cancer in a supermultiplicative manner (OR for the presence of both ADPRT 762Ala/Ala and XRCC1 399Gln/Gln genotypes, 5.91; 95% CI, 2.09-16.72), although the XRCC1 polymorphism itself was not associated with the risk. In conclusion, the ADPRT Val762Ala polymorphism plays an important role in smoking-related lung cancer and the XRCC1 Arg399Gln polymorphism may serve as a risk modifier.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Human cancer can be initiated by DNA damage caused by UV, ionizing radiation, and environmental chemical agents. However, humans have developed a set of complex DNA repair systems to safeguard the integrity of genome by defending harmful consequences of DNA damage. Among the DNA repair systems, the base excision repair (BER) pathway is one important mechanism that repairs DNA damage resulting from chemical alterations of a single base, such as methylated, oxidized, or reduced bases, and rectifies single-strand interruptions in DNA (1, 2). BER includes two major processes (i.e., excision of damaged base residues and core BER reaction, including strand incision at the abasic site, one-nucleotide gap-filling reaction, and sealing of the remaining nick; ref. 2). It is well known that a number of proteins are involved in these steps, of which ADPRT and XRCC1 play key roles. In response to DNA damage generated by genotoxic agents, ADPRT specifically binds to DNA strand breaks where it is autoactivated and recruits XRCC1-Lig3{alpha} complex (1, 3). It has been shown that interactions of ADPRT with XRCC1 as well as other partner proteins such as Polß are critical for stimulating and executing BER processes (3, 4).

Genetic polymorphisms have been identified in both ADPRT and XRCC1 genes. There are at least 38 reported variants in ADPRT (http://snp500cancer.nci.nih.gov), one of which is a T-to-C transition at codon 762 of ADPRT located in the sixth helix of catalytic domain that causes Val-to-Ala amino acid substitution. Although most of the functional relevance of these variants remain unknown, a recent study showed that the Val762Ala polymorphism is associated with altered ADPRT function, with the Ala allele contributing to significantly low poly(ADP-ribosyl)ation activities in an allele dosage-dependent manner (5). The low ADPRT activity due to the polymorphism is expected to reduce its ability to recruit XRCC1 and other related proteins. There are at least 17 XRCC1 variants identified to date (http://snp500cancer.nci.nih.gov), one of which is a G-to-A single nucleotide polymorphism (SNP) at codon 399 resulting in Arg-to-Gln amino acid change (6). Although biochemical and biological characteristics of these XRCC1 variants are not fully determined, the Arg399Gln variation is situated within the BRCT-1 region harboring the ADPRT binding domain (6) that is likely to affect functional interaction between XRCC1 and ADPRT. An altered DNA repair activity has been suggested to be associated with the XRCC1 polymorphism (7, 8)

Based on the interactive role that ADPRT and XRCC1 play at molecular level in BER activities and reported functional relevance of their variants, we hypothesized that the ADPRT Val762Ala and XRCC1 Arg399Gln polymorphisms may contribute to susceptibility to carcinogenesis. In this study, we specifically examined whether these two polymorphisms play an interactive role in the risk of lung cancer. We chose lung cancer as our disease model because the initiation of carcinogenesis by DNA damage caused by genotoxic compounds mostly found in cigarette smoke is well established in this cancer (9).


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Study Population. This hospital-based, case-control study consisted of 1,000 patients with lung cancer and 1,000 cancer-free controls. All subjects were unrelated ethnic Han Chinese. The characteristics of the study subjects have been described previously (10). Briefly, the patients with newly diagnosed, histopathologically confirmed, and previously untreated (by radiotherapy or chemotherapy) primary lung cancer were recruited between January 1997 and June 2002 at Cancer Hospital, Chinese Academy of Medical Sciences (Beijing, China). There were no age, sex, stage, or histology restrictions; however, patients with previous cancer or metastasized cancer from other organs were excluded. The controls were randomly selected from a pool of cancer-free subjects recruited from a nutritional survey conducted in the same region during the same time period as the cases were collected. The selection criteria include no prior history of cancer, and controls were frequency matched to the cases by age (±5 years) and sex. At recruitment, informed consent was obtained from each subject who was then interviewed for detailed information on demographic characteristics and lifetime history of tobacco use. The study was approved by the institutional review board of the Cancer Institute and Hospital.

Genotype Analysis. Genotypes were analyzed using PCR-based RFLP methods done without knowledge of case/control status of the subjects. The PCR primers for amplifying DNA containing the ADPRT Val762Ala polymorphism site were ADPRTF5'-tttgctcctccaggccaacg-3' and ADPRTR5'-catcgatgggatccttgctgct-3', which produce a 110-bp fragment. To induce a restrict endonuclease site, we changed the 3' end of primer ADPRTF from agg to acg which created a BstuI cutting site. Amplification was accomplished with a 25-µL reaction mixture consisted of 50 ng template DNA, 0.2 µmol/L each primer, 0.2 mmol/L each deoxynucleotide triphosphate, 2.0 mmol/L MgCl2, and 1.0 unit Taq DNA polymerase with 1 x reaction buffer (Promega, Madison, WI). The reaction was carried out in the following conditions: an initial melting step of 5 minutes at 94°C, followed by 35 cycles of 30 seconds at 94°C, 30 seconds at 62°C, and 45 seconds at 72°C, and a final elongation step of 7 minutes at 72°C. The restriction enzyme BstuI (New England Biolabs, Inc., Beverly, MA) was used to distinguish ADPRT Val762Ala genotypes. The 762Val allele produces a single band representing the entire 110-bp fragments, and the variant 762Ala allele had 90- and 20-bp fragments because it gains a BstuI site. The Val762Ala polymorphism revealed by PCR-RFLP analysis was further confirmed by DNA sequencing. Genotyping analysis of the XRCC1 Arg399Gln polymorphism was the same as described previously (11). A 15% of masked, random selected samples of the cases and controls were tested twice by different technical persons, and the results were concordant for all of the masked duplicate sets.

Statistical Analysis. The {chi}2 test was used to examine differences in demographic variables, smoking, and distribution of genotypes between cases and controls. The associations between genotype and risk of lung cancer were estimated by calculating odds ratio (OR) and their 95% confidence interval (95% CI) with unconditional logistic regression models. The ORs were adjusted for age, sex, and pack-years smoked. Light, moderate, and heavy smokers were categorized by using the 25th and 75th percentile pack-year [(cigarettes per day/20) x (years smoked)] values of the controls as the cutoff points (i.e., ≤16, 16-28, and >28 pack-years). We tested the null hypotheses of multiplicative gene-gene and gene-smoking interactions by evaluating departures from multiplicative joint effect models (12). A more than multiplicative joint effect was suggested when OR11 > OR10 x OR01. Departures from these multiplicative models were assessed by including main effect variables and their product terms in the logistic regression model. The homogeneity test was done to compare the difference between smoking-related ORs among different genotypes or between the product of related ORs and the joint effect OR. All analyses were done with the computer programs of Statistical Analysis System (version 6.12; SAS Institute, Cary, NC).


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Subject Characteristics. The demographic information on study subjects is summarized in Table 1. No statistically significant differences were found between the cases and controls in terms of age and sex distributions. However, as expected, more smokers were represented in the cases compared with the controls (65.0% versus 51.1%; P < 0.0001). In addition, the cases had higher values of pack-years smoked than the controls; 65.1% of smokers among the cases smoked > 28 pack-years, whereas this value was 33.5% among the controls (P < 0.0001). Among the cases, 448 (44.8%) were classified as squamous cell carcinoma, 297 (29.7%) as adenocarcinoma, and 255 (25.5%) as other type, including undifferentiated cancer (n = 90), bronchioalveolar carcinoma (n = 92), and mixed cell carcinoma (n = 73).


View this table:
[in this window]
[in a new window]

  		Table 1. Frequency distribution of select characteristics by case control status

 
Association with Individual Single Nucleotide Polymorphism. Genotyping results showed that the allele frequencies for ADPRT 762Ala and XRCC1 399Gln, respectively, were 0.389 and 0.279 in controls and 0.439 and 0.284 in cases. The genotype distributions of both ADPRT and XRCC1 in the cases and controls were consistent with Hardy-Weinberg equilibrium. The frequencies for ADPRT Val762Ala genotypes among the cases were statistically significantly different from those among controls ({chi}2 = 10.97, P = 0.004), and this difference was mainly due to higher frequency of the Ala/Ala genotype among the cases (Table 2). Multivariate regression analyses showed that subjects carrying the ADPRT Ala/Ala genotype had a 1.68-fold increased risk of lung cancer (95% CI, 1.27-2.23; P = 0.001) compared with those carrying the Val/Val genotype, whereas no significantly increased risk was associated with the Val/Ala heterozygous genotype (OR, 1.17; 95% CI, 0.95-1.43), suggesting a possible recessive effect of the polymorphism in ADPRT. The risk associated with the Ala/Ala genotype was then compared among different subtypes of lung cancer, and significantly increased risk was observed in lung squamous cell carcinoma (OR, 2.17; 95% CI, 1.49-3.14) and adenocarcinoma (OR, 1.54; 95% CI, 1.06-2.30) but not other types (OR, 1.48; 95% CI, 0.95-2.31). However, the distributions of XRCC1 Arg399Gln genotypes were not significantly different between the cases and controls and the XRCC1 variant genotypes were not associated with increased risk of lung cancer (Table 2).


View this table:
[in this window]
[in a new window]

  		Table 2. Genotype frequencies of ADPRT and XRCC1 among cases and controls and their association with lung cancers

 
Gene-Smoking Interaction. We next analyzed the joint effect of the ADPRT Val762Ala or XRCC1 Arg399Gln polymorphism and tobacco smoking. Because the Val/Ala heterozygous genotype was not associated with increased risk, this genotype was combined with the Val/Val genotype as reference group for analysis. A supermultiplicative joint effect was found between the ADPRT Val762Ala polymorphism and smoking (Table 3). Among nonsmokers, the ADPRT Ala/Ala genotype was not associated with increased lung cancer risk; however, among smokers, subjects carrying the Val/Val genotype had an OR of 4.32 (95% CI, 2.90-6.44) that was significantly higher than the OR among smokers carrying the Val/Val or Val/Ala genotype (OR, 2.22; 95% CI, 1.74-2.84; P < 0.001, test for homogeneity). Because the OR for the presence of both smoking and Ala/Ala genotype was greater than the product of OR for smoking and OR for the genotype (P < 0.001), these data clearly suggested a supermultiplicative joint effect between smoking and the ADPRT polymorphism. Moreover, when the risk associated with the ADPRT polymorphism were further evaluated within strata of ≤16, 16-28, and >28 pack-years smoked, a supermultiplicative joint effect between the susceptible genotype and categories of pack-years smoked was observed; the ORs were 1.02, 1.27, and 4.49, respectively, for the Val/Val or Val/Ala genotype, but 1.35, 2.46, and 17.09, respectively, for the Ala/Ala genotype (P for trend < 0.001). However, there was no such an effect between the XRCC1 Arg399Gln polymorphism and smoking (either smoking status or number of pack-years; data not shown).


View this table:
[in this window]
[in a new window]

  		Table 3. Risk of lung cancer associated with ADPRT genotypes by smoking status

 
Gene-Gene Interaction. Because ADPRT functionally interacts with XRCC1 in BER processes, we therefore evaluated the joint effect between the ADPRT and XRCC1 genotypes in the risk of lung cancer (Table 4). We found that the cases with the ADPRT Ala/Ala genotype were also more likely to have the XRCC1 Gln/Gln genotype than the controls (2.0% versus 0.5%; P = 0.017). Evidence for a supermultiplicative joint effect of the SNPs in ADPRT and XRCC1 comes from the fact that the OR for subjects with the ADPRT Ala/Ala and XRCC1 Gln/Gln genotypes versus subjects with the ADPRT Val/Val and XRCC1 Arg/Arg genotypes; that is, 5.91 (Table 4), is larger than the product of the OR for subjects with the ADPRT Ala/Ala genotype versus the ADPRT Val/Val genotype and the OR for subject with the XRCC1 Gln/Gln genotype versus XRCC1 Arg/Arg genotype (i.e., 1.68 x 1.17 = 1.97; Table 2; P = 0.018). These results clearly indicate that a more than multiplicative joint effect between the ADPRT Ala/Ala and XRCC1 Gln/Gln genotype exists in the risk of developing lung cancer (12).


View this table:
[in this window]
[in a new window]

  		Table 4. Risk of lung cancer associated with ADPRT genotypes by XRCC1 genotype among 1,000 patients and 1,000 controls

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
DNA repair systems play a key role in protecting against carcinogenesis and genetic defect in DNA repair can cause human cancer (1). Accumulating evidence shows that reduced DNA repair capacity resulting from genetic polymorphism is associated with increased risk of lung cancer (13). Our previous study has shown that SNPs in XPD, a gene that plays important role in nucleotide excision repair pathway, increases susceptibility to lung cancer in this Chinese population (10). The present study extends our findings to SNPs in BER genes, showing that the functional polymorphism in the ADPRT catalytic domain may have a great impact on risk for the development of lung cancer. A 4.32-fold increased lung cancer risk associated with the variant ADPRT 762Ala/Ala genotype among smokers, in which a supermultiplicative joint effect between the ADPRT polymorphism and cigarette smoking was evident, is an excellent example for gene-environment interaction that may have played an important role in the etiology of lung cancer in this Chinese population. Moreover, a supermultiplicative joint effect between two functional polymorphisms of the ADPRT and XRCC1 genes provides the rationale of studying underlying genetic susceptibility to tobacco-induced lung cancer.

ADPRT is a DNA-binding protein involved in the regulation of BER by detecting DNA strand breaks and poly(ADP-ribosyl)ating nuclear acceptor proteins (including itself) that relate to DNA repair programs and/or apoptosis decision (2, 14). Previous study has shown that ADPRT activities of lung cancer patients were lower than those of cancer-free individuals (15). Upon binding to DNA, ADPRT becomes auto-poly(ADP-ribosyl)ated, allowing itself to interact with other proteins involved in BER. Because the 762Val-to-Ala substitution located within the COOH-terminal catalytic domain is associated with deficient poly(ADP-ribosyl)ation activity (5), this amino acid change may reduce the BER capacity and therefore cause genome instability. Our result showing an association between the 762Ala/Ala genotype and increased risk of lung cancer is consistent with this functional relevance. Our findings are also consistent with previously published studies, in which the ADPRT Val762Ala polymorphism has been reported to be associated with increased risk of other cancers, including esophageal cancer (16) and prostate cancer (5).

To date, there is only one published lung cancer study reporting that the ADPRT haplotypes of three SNPs (codons 81, 284, and 762) were not associated with increased risk in a Korean population (17). The discrepancy between this study and ours might reflect the differences in genetic background, carcinogen exposure in different populations or just simply sample sizes (only 352 cases and 352 controls in the Korean study). Tobacco smoke contains various carcinogens that can cause DNA damage (9). Theoretically, if the ADPRT 762Ala variant actually diminishes BER capacity, smokers carrying the ADPRT 762Ala/Ala homozygous variant genotype will be at higher risk for lung cancer than those carrying the wild-type genotype. Indeed, we found a supermultiplicative joint effect of the ADPRT 762Ala/Ala genotype and smoking in a dose-response manner, with the risk being the highest among heavy smokers who carried the ADPRT 762Ala/Ala genotype. Therefore, our findings are biologically plausible.

The XRCC1 Arg399Gln polymorphism has been extensively studied in many cancer sites including lung cancer, but the results are conflicting (reviewed in ref. 18). In 1,000 cases and 1,000 controls of a Han Chinese population, we failed to observe any association between the XRCC1 Arg399Gln polymorphism (alone or in combination with smoking) and risk of lung cancer. These results are generally consistent with previous findings in a relatively large lung cancer study (19). However, it is interesting that our data suggest that the XRCC1 399Gln variant modified lung cancer risk associated with the ADPRT Val762Ala polymorphism. The supermultiplicative joint effect between these two SNPs suggests that they are likely to act in the same causal pathway (12). This observation is also in agreement with the functional interaction of ADPRT and XRCC1 in BER, in which ADPRT directly interacts with XRCC1 through the ADPRT binding domain in the BRCT-1 region of XRCC1 (4), whereas XRCC1 interacts preferentially with autoribosylated ADPRT, distinguished by a degenerate consensus motif for interaction with poly(ADP-ribose) located in the BRCT-1 domain (4). If a cell carries functional polymorphisms in both of the genes that affect ADPRT autoactivation and physical connection between ADPRT and XRCC1, then a multiplicative joint effect is to be expected. Whether these genetic polymorphisms actually affect the interaction between ADPRT and XRCC1 proteins and the overall BER activity warrant further investigations.

Genetic polymorphisms often vary with ethnicity. In this study with 1,000 healthy controls, we found that the ADPRT 762Ala allele frequency was 0.389 and that Ala/Ala homozygotes accounted for 13.7% of the Han Chinese population studied, compared with 0.145 and 2% among U.S. Caucasians and 0.045 and 0% among African Americans (5). The ADPRT 762Ala allele frequency was shown to be 0.443 in a Korean population but the genotype frequency is unavailable in this study (17). Distribution of XRCC1 Arg399Gln polymorphism also displays an ethnic difference. In the present study, we observed frequencies of 0.279 for the XRCC1 399Gln allele and 8.9% for the Gln/Gln genotype, which are very similar to other studies in Chinese population (20, 21), but significantly lower than those reported in a Caucasian population (0.335 and 11.5%, respectively, n = 1240; P < 0.05; ref. 19). Ethnic variation in the ADPRT and XRCC1 genotype distribution warrants additional comparative studies to confirm our results.

In summary, our study shows a significant association between a functional polymorphism in ADPRT and increased risk of developing lung cancer in a Han Chinese population. The increase in risk of lung cancer associated with this ADPRT polymorphism was more pronounced among smokers, displaying a supermultiplicative gene-environment joint effect. Furthermore, we observed a more than multiplicative interaction between the ADPRT and XRCC1 polymorphisms. Our findings suggest that deficient BER may play an important role in the development of lung cancer.


   Acknowledgments
 
Grant support: National Natural Science Foundation grant 30128020, National "863" High Technology Project grant 2002BA711A06, and State Key Basic Research Program grant 2004CB518701.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   Footnotes
 
Note: X. Zhang and X. Miao contributed equally to this work.

Received 9/29/04. Revised 11/18/04. Accepted 11/21/04.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Hoeijmakers JHJ. Genome maintenance mechanisms for preventing cancer. Nature (London) 2001;411:366–74.[CrossRef][Medline]
  2. Wood RD, Mitchell M, Sgouros J, Lindahl T. Human DNA repair genes. Science (Washington DC) 2001;291:1284–9.[Abstract/Free Full Text]
  3. Caldecott KW. XRCC1 and DNA strand break repair. DNA Repair (Amst.) 2003;2:955–69.
  4. Masson M, Niedergang C, Schreiber V, Muller S, Menissier-de Murcia J, de Murcia G. XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol 1998;18:3563–71.[Abstract/Free Full Text]
  5. Lockett KL, Hall MC, Xu J, et al. The ADPRT V762A genetic variant contributes to prostate cancer susceptibility and deficient enzyme function. Cancer Res 2004;64:6344–8.[Abstract/Free Full Text]
  6. Shen MR, Jones IM, Mohrenweiser H. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res 1998;58:604–8.[Abstract/Free Full Text]
  7. Lunn RM, Langlois RG, Hsieh LL, Thompson CL, Bell DA. XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res 1999;59:2557–61.[Abstract/Free Full Text]
  8. Abdel-Rahman SZ, El-Zein RA. The 399 Gln polymorphism in the DNA repair gene XRCC1 influences the genotoxic response induced in human lymphocytes by the tobacco-specific nitrosamine NNK. Cancer Lett 2000;159:63–71.[CrossRef][Medline]
  9. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 1999;91:1194–210.[Abstract/Free Full Text]
  10. Liang G, Xing D, Miao X, et al. Sequence variations in the DNA repair gene XPD and risk of lung cancer in a Chinese population. Int J Cancer 2003;105:669–73.[CrossRef][Medline]
  11. Xing D, Qi J, Miao X, Lu W, Tan W, Lin D. Polymorphisms of DNA repair genes XRCC1 and XPD and their associations with risk of esophageal squamous cell carcinoma in a Chinese population. Int J Cancer 2002;100:600–5.[CrossRef][Medline]
  12. Brennan P. Gene-environment interaction and etiology of cancer: what does it mean and how we measure it. Carcinogenesis (Lond.) 2002;23:381–7.[Abstract/Free Full Text]
  13. Spitz MR, Wei Q, Dong Q, Amos CI, Wu X. Genetic susceptibility to lung cancer: the role of DNA damage and repair. Cancer Epidemiol Biomarkers Prev 2003;12:689–98.[Free Full Text]
  14. Yu SW, Wang H, Poitras MF, et al. Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science (Washinton DC) 2002;297:259–63.
  15. Pero RW, Johnson DB, Miller DG, et al. Adenosine diphosphate ribosyl transferase responses to a standardized dose of hydrogen peroxide in the mononuclear leukocytes of patients with a diagnosis of cancer. Carcinogenesis (Lond.) 1989;10:1657–64.[Abstract/Free Full Text]
  16. Hao B, Wang H, Zhou K, et al. Identification of genetic variants in base excision repair pathway and their associations with risk of esophageal squamous cell carcinoma. Cancer Res 2004;64:4378–84.[Abstract/Free Full Text]
  17. Choi JE, Park SH, Jeon HS, et al. No association between haplotypes of three variants (codon 81, 284, and 762) in poly(ADP-ribose) polymerase gene and risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev 2003;12:947–9.[Free Full Text]
  18. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and association with cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:1513–30.[Abstract/Free Full Text]
  19. Zhou W, Liu G, Miller DP, et al. Polymorphisms in the DNA repair genes XRCC1 and ERCC2, smoking, and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2003;12:359–65.[Abstract/Free Full Text]
  20. Shen H, Xu Y, Qian Y, et al. Polymorphisms of the DNA repair gene XRCC1 and risk of gastric cancer in a Chinese population. Int J Cancer 2000;88:601–6.[CrossRef][Medline]
  21. Chen S, Tang D, Xue K, et al. DNA repair gene XRCC1 and XPD polymorphisms and risk of lung cancer in a Chinese population. Carcinogenesis (Lond.) 2002;23:1321–5.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 FASEB J.Home page
J. Lu, S. Zhang, D. Chen, H. Wang, W. Wu, X. Wang, Y. Lei, J. Wang, J. Qian, W. Fan, et al.
Functional characterization of a promoter polymorphism in APE1/Ref-1 that contributes to reduced lung cancer susceptibility
FASEB J, October 1, 2009; 23(10): 3459 - 3469.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Wu, Z. Hu, D. Yu, L. Huang, G. Jin, J. Liang, H. Guo, W. Tan, M. Zhang, J. Qian, et al.
Genetic Variants on Chromosome 15q25 Associated with Lung Cancer Risk in Chinese Populations
Cancer Res., June 15, 2009; 69(12): 5065 - 5072.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
R. McKean-Cowdin, J. Barnholtz-Sloan, P. D. Inskip, A. M. Ruder, M. Butler, P. Rajaraman, P. Razavi, J. Patoka, J. K. Wiencke, M. L. Bondy, et al.
Associations between Polymorphisms in DNA Repair Genes and Glioblastoma
Cancer Epidemiol. Biomarkers Prev., April 1, 2009; 18(4): 1118 - 1126.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
W.-Q. Li, L. Zhang, J.-L. Ma, Y. Zhang, J.-Y. Li, K.-F. Pan, and W.-C. You
Association between genetic polymorphisms of DNA base excision repair genes and evolution of precancerous gastric lesions in a Chinese population
Carcinogenesis, March 1, 2009; 30(3): 500 - 505.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F.-Y. Chiang, C.-W. Wu, P.-J. Hsiao, W.-R. Kuo, K.-W. Lee, J.-C. Lin, Y.-C. Liao, and S.-H. H. Juo
Association between Polymorphisms in DNA Base Excision Repair Genes XRCC1, APE1, and ADPRT and Differentiated Thyroid Carcinoma
Clin. Cancer Res., September 15, 2008; 14(18): 5919 - 5924.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. Gao, D. K. Price, T. Sissung, E. Reed, and W. D. Figg
Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1
Mol. Cancer Ther., May 1, 2008; 7(5): 1246 - 1250.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Yu, X. Zhang, J. Liu, P. Yuan, W. Tan, Y. Guo, T. Sun, D. Zhao, M. Yang, J. Liu, et al.
Characterization of Functional Excision Repair Cross-Complementation Group 1 Variants and Their Association with Lung Cancer Risk and Prognosis
Clin. Cancer Res., May 1, 2008; 14(9): 2878 - 2886.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. M. Hoskins, E. Marcuello, A. Altes, S. Marsh, T. Maxwell, D. J. Van Booven, L. Pare, R. Culverhouse, H. L. McLeod, and M. Baiget
Irinotecan Pharmacogenetics: Influence of Pharmacodynamic Genes
Clin. Cancer Res., March 15, 2008; 14(6): 1788 - 1796.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
S. Beneke and A. Burkle
Poly(ADP-ribosyl)ation in mammalian ageing
Nucleic Acids Res., December 3, 2007; 35(22): 7456 - 7465.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
M. C. Stern, D. V. Conti, K. D. Siegmund, R. Corral, J.-M. Yuan, W.-P. Koh, and M. C. Yu
DNA Repair Single-Nucleotide Polymorphisms in Colorectal Cancer and their Role as Modifiers of the Effect of Cigarette Smoking and Alcohol in the Singapore Chinese Health Study
Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2363 - 2372.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
A. G. Schwartz, G. M. Prysak, C. H. Bock, and M. L. Cote
The molecular epidemiology of lung cancer
Carcinogenesis, March 1, 2007; 28(3): 507 - 518.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. A. Bewick, M. S.C. Conlon, and R. M. Lafrenie
Polymorphisms in XRCC1, XRCC3, and CCND1 and Survival After Treatment for Metastatic Breast Cancer
J. Clin. Oncol., December 20, 2006; 24(36): 5645 - 5651.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Sun, Y. Gao, W. Tan, S. Ma, X. Zhang, Y. Wang, Q. Zhang, Y. Guo, D. Zhao, C. Zeng, et al.
Haplotypes in Matrix Metalloproteinase Gene Cluster on Chromosome 11q22 Contribute to the Risk of Lung Cancer Development and Progression
Clin. Cancer Res., December 1, 2006; 12(23): 7009 - 7017.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Landi, F. Gemignani, F. Canzian, V. Gaborieau, R. Barale, D. Landi, N. Szeszenia-Dabrowska, D. Zaridze, J. Lissowska, P. Rudnai, et al.
DNA Repair and Cell Cycle Control Genes and the Risk of Young-Onset Lung Cancer.
Cancer Res., November 15, 2006; 66(22): 11062 - 11069.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
C. Li, Z. Liu, L.-E Wang, S. S. Strom, J. E. Lee, J. E. Gershenwald, M. I. Ross, P. F. Mansfield, J. N. Cormier, V. G. Prieto, et al.
Genetic variants of the ADPRT, XRCC1 and APE1 genes and risk of cutaneous melanoma
Carcinogenesis, September 1, 2006; 27(9): 1894 - 1901.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. D. Kennedy and A. D. D'Andrea
DNA Repair Pathways in Clinical Practice: Lessons From Pediatric Cancer Susceptibility Syndromes
J. Clin. Oncol., August 10, 2006; 24(23): 3799 - 3808.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
R. J. Hung, J. Hall, P. Brennan, and P. Boffetta
Genetic Polymorphisms in the Base Excision Repair Pathway and Cancer Risk: A HuGE Review
Am. J. Epidemiol., November 15, 2005; 162(10): 925 - 942.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
A. G. Casson, Z. Zheng, S. C. Evans, P. J. Veugelers, G. A. Porter, and D. L. Guernsey
Polymorphisms in DNA repair genes in the molecular pathogenesis of esophageal (Barrett) adenocarcinoma
Carcinogenesis, September 1, 2005; 26(9): 1536 - 1541.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhang, X.
Right arrow Articles by Lin, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, X.
Right arrow Articles by Lin, D.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online